Form 4: Caribou Biosciences Director Sacks Granted Stock Options

Caribou Biosciences Director Natalie Sacks was granted options to purchase 45,000 shares of common stock at an exercise price of $1.80 per share.

Summary

• Natalie Sacks, a Director of Caribou Biosciences, Inc. (CRBU), was granted an option to purchase 45,000 shares of common stock.
• The exercise price for these options is $1.80 per share.
• The options were granted on February 20, 2026, and will expire on February 19, 2036.
• The shares subject to this option will vest over time, with one-twelfth vesting on each monthly anniversary of the grant date.
• The option will be fully vested by February 20, 2027, contingent on Ms. Sacks continuing to provide service to the Issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine compensation event that aligns the director's interests with long-term shareholder value, reflecting a standard practice rather than a significant positive or negative operational development.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Caribou Biosciences.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The vesting schedule for the granted options indicates an expectation for the reporting person to continue providing service to Caribou Biosciences through at least February 20, 2027, aligning the director's long-term commitment with the company's future performance.

Industry Context

StockSavvy.ai notes that stock option grants are a common form of executive and director compensation in the biotechnology industry, serving to align leadership incentives with long-term company performance and shareholder value. This practice is widely adopted to retain key talent and motivate strategic decision-making.

Comparison to Industry Standards

• StockSavvy.ai notes that granting stock options to directors is a common practice across the biotechnology and broader corporate landscape, serving to align leadership incentives with long-term company performance.
• The specific terms, such as the exercise price and vesting schedule, are generally consistent with typical compensation structures for non-employee directors in similar-sized public companies, though direct comparisons to specific projects or results are not provided in this filing.

Stakeholder Impact

• Shareholders may benefit from increased alignment between the director's personal financial interests and the company's long-term stock performance.
• The grant incentivizes the director to contribute to the company's success over the vesting period.

Next Steps

• The options will vest monthly over the next year, with full vesting expected by February 20, 2027, assuming continued service.

Key Dates

Keywords

Caribou Biosciences, CRBU, Natalie Sacks, stock options, insider transaction, Form 4, director compensation, equity compensation